甘草酸二铵注射液与水飞蓟宾胶囊治疗慢性乙型肝炎对患者肝纤维化的影响OA

Objective To explore the effects of Diammonium Glycyrrhizinate injection and Silybin capsule on hepatic fibrosis in patients with chronic hepatitis B.Methods A total of 96 patients with chronic hepatitis B admitted to the People's Hospital of Port District from January 2021 to June 2022 were selected as the study objects,and were divided into control group and observation group according to random number table method,with 48 cases in each group.The control group was treated with diammonium glycyrrhizinate injection,and the observation group was treated with silybin capsule.The clinical efficacy,liver function indexes,liver fibrosis indexes,inflammation and oxidative stress indexes,liver function injury degree,quality of life and adverse reactions were compared between the two groups.Results The effective rate of the observation group was significantly higher than that of the control group(P＜0.05).After treatment,the levels of bilirubin(TBil),alanine aminotransferase(ALT),aspartate aminotransferase(AST),alkaline phosphatase(ALP),hyaluronic acid(HA),laminin(LN),type Ⅲ procollagen(PC-Ⅲ),type Ⅳcollagen(C-Ⅳ),interleukin-4(IL-4),interleukin-10(IL-10))and malondialdehyde(MDA)in the observation group were significantly lower than those in control group,and the scores of superoxide dismutase(SOD)and EORTC Quality of Life Scale(QLQ-C30)were significantly higher than those in control group,with statistical significance(P＜0.05).After treatment,the proportion of patients with no liver injury and mild liver injury in observation group was significantly higher than that in control group(P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion Diammonium Glycyrrhizinate injection and Silybin capsule have certain clinical effects in the treatment of chronic hepatitis B,but Silybin capsule is significantly better than Diammonium Glycyrrhizinate injection in improving liver function,liver fibrosis and quality of life.